Skip to main content

Table 3 Included studies: baseline patient characteristics

From: Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings

 

Lasmiditan vs placebo

Rimegepant vs placebo

Ubrogepant vs placebo

Characteristic

SPARTAN Kuca et al. 2018

[15]

SAMURAI Goadsby

et al. 2019

[16]

CENTURION Ashina

et al. 2021

[17]

MONONOFU Sakai

et al. 2021

[18]

Färkkilä

et al. 2012 [19]

Study 301

Lipton

et al. 2018

[20]

Study 302

Lipton

et al. 2019

[21]

Study 303 Croop

et al. 2019

[22]

Marcus

et al. 2014

[23]

ACHIEVE I Dodick

et al. 2019

[24]

ACHIEVE II Lipton

et al. 2019

[25]

Voss

et al. 2016

[26]

Na (baseline)

1856

2583

1471

691

321

1162b

1072

1351

320

1436

1465

425

Female, n (%)

1552

(83.6)

2174

(84.2)

1236

(84)

574

(83.1)

277 (86.3)

NA

(85.5)

951 (88.7)

1147

(84.9)

277

(86.6)

1266 (88.2)

1317 (89.9)

372 (87.5)

Meanc age, years (range)d

41.4–42.4

41.8–43.4

41.0–42.0

44.7–45.7

39.5–42.0

41.6d

40.2–40.9

40.0–40.3

37.9–38.5

40.1–40.9

41.2–41.7

40.5–41.9

Meanc duration of disease, years (range)d

18.9–19.7

17.6–19.2

NA

23.7–24.7

NA

NA

NA

NA

NA

17.9–19.1

18.1–19.2

NA

  1. aData are from patients receiving placebo or the active treatments included in the NMA; bNumber randomised; cMean for total study population; dRange is the range of mean values across each treatment group of interest
  2. NA not available, NMA network meta-analysis